WO2024020063A3 - Anti-hrf antibodies - Google Patents

Anti-hrf antibodies Download PDF

Info

Publication number
WO2024020063A3
WO2024020063A3 PCT/US2023/028081 US2023028081W WO2024020063A3 WO 2024020063 A3 WO2024020063 A3 WO 2024020063A3 US 2023028081 W US2023028081 W US 2023028081W WO 2024020063 A3 WO2024020063 A3 WO 2024020063A3
Authority
WO
WIPO (PCT)
Prior art keywords
hrf
antibodies
monoclonal antibodies
therapeutically
fragments
Prior art date
Application number
PCT/US2023/028081
Other languages
French (fr)
Other versions
WO2024020063A2 (en
Inventor
Toshiaki Kawakami
Toshiaki Maruyama
Original Assignee
La Jolla Institute For Immunology
Abwiz Bio Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Institute For Immunology, Abwiz Bio Inc. filed Critical La Jolla Institute For Immunology
Publication of WO2024020063A2 publication Critical patent/WO2024020063A2/en
Publication of WO2024020063A3 publication Critical patent/WO2024020063A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Monoclonal antibodies reactive to human histamine releasing factor (HRF) protein and fragments thereof are provided for use diagnostically and therapeutically. These monoclonal antibodies are shown to be strong inhibitors of HRF-IGE interactions and the inflammatory response.
PCT/US2023/028081 2022-07-19 2023-07-18 Anti-hrf antibodies WO2024020063A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263390603P 2022-07-19 2022-07-19
US63/390,603 2022-07-19

Publications (2)

Publication Number Publication Date
WO2024020063A2 WO2024020063A2 (en) 2024-01-25
WO2024020063A3 true WO2024020063A3 (en) 2024-03-07

Family

ID=89618455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/028081 WO2024020063A2 (en) 2022-07-19 2023-07-18 Anti-hrf antibodies

Country Status (1)

Country Link
WO (1) WO2024020063A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180312588A1 (en) * 2017-04-24 2018-11-01 Kite Pharma, Inc. Humanized antigen-binding domains and methods of use
US20200369750A1 (en) * 2010-03-31 2020-11-26 La Jolla Institute For Allergy And Immunology Histamine-releasing factor (hrf), hrf-receptor and methods of modulating inflammation
US20220056124A1 (en) * 2018-09-05 2022-02-24 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against endotrophin and the use thereof
US20220135701A1 (en) * 2019-04-19 2022-05-05 Genentech, Inc. Anti-mertk antibodies and their methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200369750A1 (en) * 2010-03-31 2020-11-26 La Jolla Institute For Allergy And Immunology Histamine-releasing factor (hrf), hrf-receptor and methods of modulating inflammation
US20180312588A1 (en) * 2017-04-24 2018-11-01 Kite Pharma, Inc. Humanized antigen-binding domains and methods of use
US20220056124A1 (en) * 2018-09-05 2022-02-24 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against endotrophin and the use thereof
US20220135701A1 (en) * 2019-04-19 2022-05-05 Genentech, Inc. Anti-mertk antibodies and their methods of use

Also Published As

Publication number Publication date
WO2024020063A2 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
Yuan et al. Pivotal role of lesional and perilesional T/B lymphocytes in pemphigus pathogenesis
Préfontaine et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells
WO2021152186A3 (en) Ccr8 antibodies for therapeutic applications
Antiga et al. Characterization of regulatory T cells in patients with dermatomyositis
Schiechl et al. Basophils trigger fibroblast activation in cardiac allograft fibrosis development
AU6760700A (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU7210994A (en) Monoclonal antibodies against the alpha pdgf receptor and uses thereof
WO2022026360A3 (en) Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
WO2024020063A3 (en) Anti-hrf antibodies
Meroni et al. Mosaic of anti-endothelial antibodies: Review of the first international workshop on anti-endothelial antibodies: clinical and pathological significance Milan, 9 November 1994
Hsu et al. CD3+ CD4–CD8–Double-negative αβ T cells attenuate lung ischemia-reperfusion injury
Hohmann et al. Antibody-mediated depletion of CCR10+ EphA3+ cells ameliorates fibrosis in IPF
JPH02288836A (en) Inhibitor of immunocyte proliferation
WO2006060719A3 (en) Use of endosialin binding proteins to isolate endosialin positive cells
Svenson et al. Cytokine vaccination: neutralising IL-1α autoantibodies induced by immunisation with homologous IL-1α
Kim et al. Surface expression of neutrophil CXCR4 is down-modulated by bacterial endotoxin
Tsujimura et al. Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus
Drouhet et al. Fungal Antigens: Isolation, Purification, and Detection
CN116970081B (en) Anti-humanized CD132 monoclonal antibody and application thereof
Asgari et al. Evaluation of Autoantibodies in patients with Systemic Sclerosis
Menzhinskaya et al. Spectrum of antibodies to reproductive hormones in threatened abortion
He et al. Dynamic observation of IL-33 and its receptors in HIV patients who received HAART
WO2023039611A3 (en) Tfr antigen binding proteins and uses thereof
WO2023034950A3 (en) Anti-hcmv antibodies and antigen-binding fragments thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23843640

Country of ref document: EP

Kind code of ref document: A2